Strengths

● The stock, which is currently worth 2019 to 0.53 times its sales, is clearly overvalued in comparison with peers.

● Over the last seven days, analysts have been revising upwards their EPS estimates for the company.


Weaknesses

● The share is close to its long-term resistance in weekly data. Therefore, the potential should be limited. However, a further bullish movement when crossing this resistance will be a positive signal.

● The stock is currently in contact with a medium-term resistance that must be gotten rid of so as to resume the upward trend.

● According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.

● The company has insufficient levels of profitability.

● Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.

● Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

● The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 33 times its estimated earnings per share for the ongoing year.

● The company is not the most generous with respect to shareholders' compensation.

● Revenue estimates are regularly revised downwards for the current and coming years.

● For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.

● For the past year, analysts have significantly revised downwards their profit estimates.